Serum Interleukin - 17A in Juvenile Idiopathic Arthritis

Not yet recruiting

• Conditions: JIA

• Registration Number: NCT05688358
• Lead Sponsor: Assiut University

Brief Summary

1. This study aims to determine the serum levels of interleukin-17A (IL-17A) in children with juvenile idiopathic arthritis (JIA)

2. Analyze the correlation between IL-17A values and disease activity, certain clinical features, and laboratory markers of inflammation.

Detailed Description

Juvenile Idiopathic Arthritis (JIA) is a group of chronic heterogenous disorders that manifests as joint inflammation in patients aged \<16 years and lasts longer than 6 weeks. Globally, approximately 3 million children and young adults are suffering from JIA with prevalence rates consistently higher in girls. The prevalence of JIA in Africa and Middle East was observed to be towards the lower range of the global estimate. (1) The precise cause and pathogenesis of JIA are unknown; however, genetic, environmental, and autoimmune factors are hypothesized to play a role in its development. (2) The condition can affect one or more joints and cause systemic symptoms such as fever or rash, as well as extra-articular inflammatory signs such as uveitis.(3)

The IL-17 cytokine superfamily is composed of 6 structurally related cytokines, namely IL-17A-F. The most investigated member of the family is IL-17A. It is synthesized by Th17 cells, γδ-T cells, NK T cells, lymphoid tissue inducer-like cells, Paneth cells, and neutrophils. IL-17A plays important roles in protection from bacterial and fungal infections and in the development of autoimmune diseases (4)

Recently, a number of studies have been conducted on the role of IL-17A in the development of chronic arthritis. It has a role both at the initial stages of joint inflammation and in the destruction of joint cartilage and bone structures.(5) It binds to its receptors on synoviocytes, endothelial cells, fibroblasts and osteoblasts and stimulates production of pro-inflammatory cytokines, chemokines and other inflammatory mediators, and also, interacts synergistically with other pro- inflammatory cytokines such as IL-1, IL-6, and tumor necrosis factor alpha.(6)

Study Timeline

• Status Verified: 2023-01
• Study First Submitted: 2023-01-07
• Study First Submitted QC: 2023-01-15
• Last Update Submitted: 2023-01-15
• Study First Posted: 2023-01-18
• Last Update Posted: 2023-01-18
• Study Start: 2023-02-01
• Primary Completion: 2025-05-01
• Study Completion: 2025-09-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

_ Patients less than 16 years at onset of disease and diagnosed with oligoarticular and polyarticular JIA, fulfilling the ILAR classificationcriteria of JIA.

• Control group will include age-and-sex-matched apparently healthy children.

Exclusion Criteria

• Patients having associated neurological or disabling diseases.

• Patients with diabetes mellitus, acute or chronic infections.
• Patients with another causes of arthritis other than JIA.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum Interleukin - 17A in juvenile idiopathic Arthritis	baseline	This study aims to determine the serum levels of interleukin-17A (IL-17A) in children with juvenile idiopathic arthritis (JIA); -Analyze the correlation between IL-17A values and disease activity, certain clinical features, and laboratory markers of inflammation